New drug cocktail shows promise for Tough-to-Treat leukemia
NCT ID NCT03041688
First seen Mar 02, 2026 · Last updated May 13, 2026 · Updated 11 times
Summary
This early-phase study tests a new drug called navtemadlin (KRT-232) combined with two standard drugs, decitabine and venetoclax, for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goal is to find the safest dose and understand side effects. About 58 adults with relapsed, refractory, or newly diagnosed AML will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Keck Medical Center of USC Pasadena
Pasadena, California, 91105, United States
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536, United States
-
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, 23298, United States
Conditions
Explore the condition pages connected to this study.